Please assess the completion status of the following clinical trial:

Trial Title: Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with diagnosis of hepatic cell carcinoma (HCC) according to the AASLD- EASL criteria~* Age \>18 years~* Advanced stage of disease defined as HCC not eligible for locoregional treatments (ab initio or following progression after such treatments)~* Liver function classified as Child-Pugh class B~* ECOG performance status \< or = 2~* Life expectancy of at least 2 months~* Adequate contraception for fertile male and female patients~* Signed informed consent~Exclusion Criteria:~* Prior exposure to sorafenib or antiangiogenesis drugs~* Concomitant diseases that contraindicate the use of sorafenib~* Gastro-intestinal bleeding in the previous 30 days~* Altered renal function(creatinine \> 1.5 x ULN), or haematological function (platelet count \< 60 x 10\^9/L, hemoglobin \< 9 g/dl)~* Serious active infections (\> grade 2 CTCAE version 3.0)~* Congestive heart failure, history of congestive heart failure, unstable angina pectoris, myocardial infarct or significant valvular heart disease or uncontrolled heart arrhythmia~* Patients who are unable or unwilling to participate in the study~* Pregnant or lactating females~* Hepatic encephalopathy of any grade

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A: Best Supportive Care (Type: ACTIVE_COMPARATOR): best supportive care
- B: Sorafenib 400 mg, twice a day + Best Supportive Care (Type: EXPERIMENTAL): sorafenib + best supportive care

Based on this trial design, predict the completion outcome and termination type (if applicable).